Ghassan A. Al-Jazayrly
Expertise in
38
conditions

Dr. Ghassan A. Al-Jazayrly

Internal Medicine
Complete Care Community Health Center
Los Angeles, CA 
Accepting New Patients
Expertise in
38
conditions
Complete Care Community Health Center
Los Angeles, CA 

Overview

Ghassan Al-Jazayrly, MD, is board certified in internal medicine and medical ongology. He currently serves as chairman and director of cancer services at Hollywood Presbyterian Medical Center and director of the research center at Glendale Memorial Hospital. As a member of several hospital committees, Dr. Al-Jazayrly stays up-to-date with the latest cancer and blood disorder advancements.

Dr. Al-Jazayrly is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Anemia, Small Cell Lung Cancer (SCLC), Lung Cancer, and Familial Colorectal Cancer.

Dr. Al-Jazayrly is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, participating in 7 clinical trials. Dr. Al-Jazayrly is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

University of California, Davis , Hematology & Oncology , 1995 - 1998

Hospital Affiliations

Hollywood Presbyterian Medical Center
Glendale Mem Hospital & Hlth Center

Languages Spoken

English
Arabic
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Complete Care Community Health Center
Los Angeles, CA 90034
Other Locations
Complete Care Community Health Center
1300 N. Vermont Ave Ste 606, Los Angeles, CA 90027
Complete Care Community Health Center
2023 West Vista Way - Suite J, Vista, CA 92083
Complete Care Community Health Center
1350 E Los Angeles Avenue, Simi Valley, CA 93065
Complete Care Community Health Center
Los Angelas, CA 90034
Complete Care Community Health Center
4849 Van Nuys Blvd Ste 102, Sherman Oaks, CA 91403
Complete Care Community Health Center
3831 Hughes Ave Ste 601, Culver City, CA 90232
Complete Care Community Health Center
365 North Pearson Drive Ste 5, Porterville, CA 93257
Complete Care Community Health Center
2595 E. Washington Blvd. Ste 106, Pasedena, CA 91107
Complete Care Community Health Center
941 S Atlantic Blvd Ste 101, Monterey Park, CA 91754
Complete Care Community Health Center
220 S Akers St Unit D, Visalia, CA 93291
Complete Care Community Health Center
2928 East Cesar Chavez Ave, Los Angeles, CA 90033
Complete Care Community Health Center
4910 Van Nuys Blvd Ste 303, Sherman Oaks, CA 91403
Complete Care Community Health Center
11100 Warner Ave Ste 200, Fountain Valley, CA 92708
Complete Care Community Health Center
7301 State St, Huntington Park, CA 90255
Complete Care Community Health Center
5831 Firestone Blvd Ste E, Southgate, CA 90280
Complete Care Community Health Center
8530 Florence Ave, Downey, CA 90240
Complete Care Community Health Center
276 N Abby Street, Fresno, CA 90034

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer
Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer
Enrollment Status: Unknown
Publish Date: February 09, 2022
Intervention Type: Drug
Study Drugs: Gedatolisib, Faslodex, Palbociclib, Zoladex
Study Phase: Phase 1
View 6 Less Clinical Trials
Similar Doctors
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (21.3 miles away)
310-794-9718
Languages Spoken:
English

Charles Bernstein is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Bernstein is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (17.5 miles away)
310-423-5161
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Albert is a primary care provider, practicing in Internal Medicine in West Hollywood, California. Dr. Albert is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Hyper IgE Syndrome, Splenectomy, and Bone Graft. Dr. Albert is currently accepting new patients.

Expertise in
16
conditions
Dr. Richard N. Channick
Internal Medicine
Expertise in
16
conditions
Dr. Richard N. Channick
Internal Medicine

Office

200 Medical Plz Ste 365B, 
Los Angeles, CA 
 (21.3 miles away)
310-825-0527
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Channick is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Channick is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Hypertension, Pulmonary Embolism, Embolectomy, and Thrombectomy.

Frequently Asked Questions about Dr. Ghassan A. Al-Jazayrly

How do I make an appointment with Dr. Ghassan A. Al-Jazayrly?

You can book an appointment with Dr. Ghassan A. Al-Jazayrly by calling their office at 310-730-6362. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ghassan A. Al-Jazayrly a top-rated expert for Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ghassan A. Al-Jazayrly is classified as an Distinguished expert for Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ghassan A. Al-Jazayrly specialize in?

While Dr. Ghassan A. Al-Jazayrly is a Internal Medicine, they have specific expertise in Anemia, Small Cell Lung Cancer (SCLC), and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Ghassan A. Al-Jazayrly accept my insurance?

Dr. Ghassan A. Al-Jazayrly accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 310-730-6362 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Al-Jazayrly's expertise for a condition
ConditionClose
    View All 34 Advanced Conditions
    View All 133 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile